{"product_id":"molecular-therapeutics-9780470019177","title":"Molecular Therapeutics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eBy taking advantage of recent advances and increased understanding in the field of human genetics, Molecular Therapeutics: 21st Century Medicine provides essential background knowledge and key literature on a broad range of novel approaches and disciplines.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"This book should be useful to lecturers who teach senior undergraduates, graduate students, and students in the biomedical sciences in general. More globally, Greenwell and McCulley's book should encourage academicians of any stripe who for some time have been honing their lectures in a niche subject area to turn their courses into textbooks.\" (\u003ci\u003eBiochemistry and Molecular Biology Education\u003c\/i\u003e, November\/December 2008)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003ePrologue\u003c\/b\u003e  \u003cp\u003e\u003cb\u003e1 Introduction\u003c\/b\u003e\u003cbr\u003e 1.1 Microbial diseases\u003cbr\u003e 1.2 Cancer and heart disease\u003cbr\u003e 1.3 Genetic diseases\u003cbr\u003e 1.4 Role of molecular biology in therapeutics\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Prenatal diagnosis and pre-implementation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Should we treat inherited diseases?\u003cbr\u003e 2.2 Genetic screening\u003cbr\u003e 2.2.1 Pre-implementation genetic diagnosis\u003cbr\u003e 2.3 Counselling\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Simple protein replacement therapy\u003c\/b\u003e\u003cbr\u003e 3.1 Preventing transfusion-transmissible infectious\u003cbr\u003e diseases in the UK\u003cbr\u003e 3.2 Ensuring the safety of organ transplants\u003cbr\u003e 3.3 Preventing transfusion-transmissible infectious\u003cbr\u003e diseases worldwide\u003cbr\u003e 3.4 HIV\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Recombinant protein production\u003c\/b\u003e\u003cbr\u003e 4.1 Choice of organism\u003cbr\u003e 4.2 Alternatives to E. coli for the production of\u003cbr\u003e recombinant proteins\u003cbr\u003e 4.3 Problems with recombinant protein production\u003cbr\u003e 4.4 All recombinants must be tested before they are\u003cbr\u003e given to humans\u003cbr\u003e 4.5 Why make recombinant proteins?\u003cbr\u003e 4.6 Recombinant products\u003cbr\u003e 4.7 Generics\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Recombinant vaccines\u003c\/b\u003e\u003cbr\u003e 5.1 Vaccine history\u003cbr\u003e 5.2 Vaccines\u003cbr\u003e 5.3 Vaccine methods\u003cbr\u003e 5.4 Types of vaccine\u003cbr\u003e 5.5 The limitations of vaccine programmes\u003cbr\u003e 5.6 The role of the WHO\u003cbr\u003e 5.7 Problems specific to developing countries\u003cbr\u003e 5.8 Economics and logistics of vaccinology\u003cbr\u003e 5.9 Recombinant vaccines\u003cbr\u003e 5.10 Rational design: bioinformatics and proteomics\u003cbr\u003e 5.11 Other interesting areas for vaccine development\u003cbr\u003e 5.12 Conclusion\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Therapeutic antibodies and immunotherapy\u003c\/b\u003e\u003cbr\u003e 6.1 Monoclonal antibodies\u003cbr\u003e 6.2 Monoclonal production\u003cbr\u003e 6.3 Therapeutic monoclonal antibodies\u003cbr\u003e 6.4 Transgenic monoclonals\u003cbr\u003e 6.5 The uses of monoclonal antibodies in therapy\u003cbr\u003e 6.6 Specific examples of therapeutic strategies\u003cbr\u003e 6.7 Other recombinant proteins used in immunotherapy\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Transgenic animals\u003c\/b\u003e\u003cbr\u003e 7.1 Why do we want to engineer the genomes of animals?\u003cbr\u003e 7.2 Experimental procedure\u003cbr\u003e 7.3 DNA constructs, insertional mutagenesis and\u003cbr\u003e homologous recombination\u003cbr\u003e 7.4 Uses of inducible and tissue-specific promoters\u003cbr\u003e 7.5 Introduction of the DNA into the cells\u003cbr\u003e 7.6 Uses of transgenics\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Transplantation: a form of gene therapy\u003cbr\u003e \u003c\/b\u003e8.1 Introduction\u003cbr\u003e 8.2 Bone marrow\u003cbr\u003e 8.3 Solid organ transplantation\u003cbr\u003e 8.4 Other cells and tissues\u003cbr\u003e 8.5 Summary of the problems associated\u003cbr\u003e with transplantation\u003cbr\u003e 8.6 Transplantation statistics\u003cbr\u003e 8.7 Legislation\u003cbr\u003e 8.8 Religious beliefs and transplantation\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Xenotransplantation\u003c\/b\u003e\u003cbr\u003e 9.1 Introduction\u003cbr\u003e 9.2 Rationale for the use of non-human donors\u003cbr\u003e 9.3 Organs from non-human primates\u003cbr\u003e 9.4 Pigs\u003cbr\u003e 9.5 Problems with pigs\u003cbr\u003e 9.6 Government legislation\u003cbr\u003e 9.7 When will xenotransplantation start?\u003cbr\u003e 9.8 Patient attitudes\u003cbr\u003e 9.9 Ethics\u003cbr\u003e 9.10 Alternatives to xenotransplants\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Reproductive cloning\u003c\/b\u003e\u003cbr\u003e 10.1 History\u003cbr\u003e 10.2 Problems\u003cbr\u003e 10.3 Why was there so much interest in Dolly?\u003cbr\u003e 10.4 Was Dolly a lone example?\u003cbr\u003e 10.5 Why is cloning useful?\u003cbr\u003e 10.6 Is human cloning a reality?\u003cbr\u003e 10.7 Why can we not produce human clones that\u003cbr\u003e are identical?\u003cbr\u003e 10.8 So why clone humans?\u003cbr\u003e 10.9 What are the ethical and moral problems?\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Stem cell therapy\u003c\/b\u003e\u003cbr\u003e 11.1 The potency of cells\u003cbr\u003e 11.2 Cloning\u003cbr\u003e 11.3 Potency of stem cells\u003cbr\u003e 11.4 Potential sources of stem cells\u003cbr\u003e 11.5 Stem cells and therapeutic cloning\u003cbr\u003e 11.6 Legislation and therapeutic cloning\u003cbr\u003e 11.7 Other sources of stem cells\u003cbr\u003e 11.8 What can be done?\u003cbr\u003e 11.9 Experiments on embryonic cells\u003cbr\u003e 11.10 Experiments on fetal tissue and cord blood\u003cbr\u003e 11.11 Stem cells from adult tissues\u003cbr\u003e 11.12 Safety and technical problems\u003cbr\u003e 11.13 Perceived scope of therapy\u003cbr\u003e 11.14 Clinical trials of stem cell therapy\u003cbr\u003e 11.15 What are the future prospects for stem cell research?\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Gene augmentation therapy\u003c\/b\u003e\u003cbr\u003e 12.1 Introduction\u003cbr\u003e 12.2 Strategy\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cbr\u003e \u003cb\u003e13 Gene therapy trials for inherited diseases\u003c\/b\u003e\u003cbr\u003e 13.1 Introduction\u003cbr\u003e 13.2 Examples of disease treated with retroviral gene therapy\u003c\/p\u003e \u003cp\u003e13.3 Cystic fibrosis\u003cbr\u003e 13.4 Animal trials with Factor IX\u003cbr\u003e 13.5 Adenoviruses have also been used to introduce\u003cbr\u003e genes into brain\u003cbr\u003e 13.6 Duchenne's muscular dystrophy\u003cbr\u003e 13.7 Problems with adenoviruses\u003cbr\u003e 13.8 The uses of adeno-associated viruses\u003cbr\u003e 13.9 Liposome vector trials\u003cbr\u003e 13.10 Trials with polymer mareix delivery\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Gene silencing technologies\u003c\/b\u003e\u003cbr\u003e 14.1 Antisense therapy\u003cbr\u003e 14.2 Triple helix (triplex) technology\u003cbr\u003e 14.3 Ribozymes\u003cbr\u003e 14.4 Small interfering RNAs (siRNAs)\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Gene therapy for cancer\u003c\/b\u003e\u003cbr\u003e 15.1 What causes cancer?\u003cbr\u003e 15.2 Cancer: a multifactorial disease\u003cbr\u003e 15.3 Cancer statistics\u003cbr\u003e 15.4 Best treatment currently available\u003cbr\u003e 15.5 Do chemo- and radiotherapy cause problems?\u003cbr\u003e 15.6 New cancer therapies\u003cbr\u003e 15.7 Cancer models in animals\u003cbr\u003e 15.8 What kinds of gene therapy can we use to\u003cbr\u003e treat cancer?\u003cbr\u003e 15.9 Perceived problems in cancer gene\u003cbr\u003e augmentation therapy\u003cbr\u003e 15.10 Gene silencing technologies and cancer\u003cbr\u003e 15.11 Conclusion\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Single-nucleotide polymorphisms (SNPs)\u003cbr\u003e and therapy\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17 Legislation, clinical trials and ethical issues\u003cbr\u003e 17.1 Legislative bodies\u003cbr\u003e 17.2 Clinical trials\u003cbr\u003e 17.3 The problems of placebo controlled trials\u003cbr\u003e 17.4 The need for informed consent\u003cbr\u003e 17.5 Trials in developing countries\u003cbr\u003e 17.6 Recent trial issues\u003cbr\u003e 17.7 Conclusion\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eEpilogue\u003cbr\u003e Sourcing references\u003cbr\u003e \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex\u003c\/b\u003e\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402257670487,"sku":"9780470019177","price":50.3,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470019177.jpg?v=1730479858","url":"https:\/\/bookcurl.com\/products\/molecular-therapeutics-9780470019177","provider":"Book Curl","version":"1.0","type":"link"}